Spiromide

Quick links to important sections

Spiromide

Method of action: Diuretic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiromide

Property Description
Active Ingredients Furosemide and Spironolactone
Form Tablet
Pharmacological Class Diuretic and Antihypertensive agent
Common Use Managing fluid retention and hypertension
Origin Synthetic

Spiromide is a prescription-only medicine (POM) categorized as a fixed-dose combination (FDC) pharmaceutical preparation designed for oral administration. It is classified as both a diuretic and an antihypertensive agent. This formulation integrates two distinct pharmacological agents within a single tablet. Other common trade names featuring this specific Furosemide and Spironolactone combination include Aldactazide and Lasilactone.

What Type of Medicine is Spiromide?

Spiromide is a dual-action drug belonging to the therapeutic classes of diuretics and antihypertensive agents, prepared as a synthetic fixed-dose combination product. Furosemide, a component of the drug, is specifically classified as a potent loop diuretic, while Spironolactone is defined as a potassium-sparing diuretic that acts as an aldosterone antagonist. This strategic pairing is clinically recognized for achieving enhanced fluid removal compared to either agent used alone.

Composition: Furosemide, Spironolactone, and Origin

The core of Spiromide consists of two active ingredients, Furosemide and Spironolactone, both of which are entirely synthetic chemical compounds. The two agents are combined to leverage their different, yet complementary, renal targets. The product is physically presented as a solid oral tablet, a form chosen for its reliability in delivering the fixed proportion of the active substances along with standard excipients.

General Purpose and Synergistic Benefit

The general purpose of the Spiromide combination is to provide a powerful synergistic diuretic effect that helps the body remove excess salt and water. This dual-action mechanism is primarily used to relieve conditions related to severe fluid retention or edema, and reliably contributes to the control of chronic hypertension. The formulation’s unique design, featuring the potassium-sparing element of Spironolactone, provides a key advantage by mitigating a common electrolyte concern associated with the potent fluid-removal capabilities of Furosemide.

Regulatory References

  1. NIH Classification of Diuretics and Antihypertensives

What side effects are possible with Spiromide?

Possible Side Effects and Safety Information

The medicine's official safety profile is structured by System-Organ-Classes and frequency classifications as detailed in regulatory documents. The most significant safety concerns revolve around fluid and electrolyte balance.


Adverse Reaction Scope

  • Key Adverse Reaction Categories: The primary effects documented relate to volume depletion (dehydration, hypovolaemia) and metabolic disturbances, specifically critical changes in potassium levels (Hyperkalaemia from Spironolactone and Hypokalaemia from Furosemide).
  • Frequency Classification (Regulatory Terms): Adverse effects classified as Very Common in official documentation include Hyponatraemia, Hypochloraemia, and Hypovolaemia. Common effects include Hyperkalaemia and symptomatic Hypotension. Rarer effects include certain blood disorders (Leukopenia) and hearing impairment.
  • System-Organ Classes Involved: Effects are officially documented across several systems, including the Metabolism and Nutrition, Nervous System (dizziness, headache), Ear and Labyrinth (tinnitus, hearing impairment), and the Reproductive System and Breast Disorders (Gynaecomastia).
  • Documented Serious Adverse Reactions: Serious reactions include life-threatening Hyperkalaemia, especially in patients with severe heart failure, the potential for Hepatic Encephalopathy in those with pre-existing liver impairment, and rare reports of severe skin reactions and Irreversible Deafness.

Safety Considerations and Restrictions

  • Population-Specific Notes: Regulatory documents specify that Older Adults are particularly susceptible to risks associated with volume depletion. Caution is noted for patients with Hepatic Impairment due to the risk of precipitating Hepatic Encephalopathy.
  • Dose- or Exposure-Related Patterns: Symptomatic hypotension is noted to be more likely at the start of treatment. Gynaecomastia is a dose-dependent effect associated with longer duration of exposure to Spironolactone.
  • Safety Restrictions: The medicine is officially contraindicated in conditions such as Anuria (absence of urine production), pre-existing Hyperkalaemia, Severe Renal Insufficiency not responsive to Furosemide, and Addison’s Disease.

This structure ensures that safety information is communicated in a neutral, label-based manner, focusing on documented physiological changes and specified constraints.

Overdose and Emergency Response

Documented Overdose Manifestations

Overdosage is formally documented to present with signs of severe fluid and volume depletion, including profound Dehydration and Hypotension (low blood pressure). Central nervous system effects such as Drowsiness, Dizziness, and Mental Confusion are also regulatory-documented manifestations. The primary physiological concern is critical electrolyte derangement, specifically Hyponatremia, Hypokalemia, and potentially life-threatening Hyperkalemia. These imbalances create the risk of severe complications, including cardiac arrhythmias and seizures. The risk of severe Hyperkalemia is specifically amplified in patients with impaired renal function.

Immediate Actions and Supportive Management

Regulatory agencies mandate that immediate medical attention be sought for any suspected overdose. Emergency services must be contacted immediately if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Management is strictly supportive in nature and requires the immediate discontinuation of the medication. Supportive care focuses on the aggressive replacement of excessive fluid and electrolyte losses and frequent monitoring of serum electrolytes and blood pressure. No specific antidote is known for this overdose, according to official labeling.

Therapeutic Uses of Spiromide

Relief and Symptom Management: What Spiromide Treats

Spiromide is used across domains where short-term symptomatic assistance is needed to address a significant burden of symptoms, primarily focusing on fluid-related distress and difficult-to-manage blood pressure. It is used for managing certain distressing symptoms, offering supportive relief. The combination is relevant for easing Edematous conditions such as those of congestive heart failure and cirrhosis of the liver, and also for mild to moderate hypertension.

This medication is commonly used to help with symptomatic relief when fluid accumulation creates noticeable physiological strain. It is applied in addressing symptom clusters related to physical discomfort from fluid retention, such as swelling, and in situations where symptoms become more noticeable due to heart failure and liver cirrhosis. The medicine also plays a role in managing symptoms of difficult-to-manage high blood pressure, known as resistant hypertension.

The application of this medication is aligned with providing supportive relief during symptomatic periods. This support contributes to improved day-to-day comfort during symptomatic phases.

Focus: Symptomatic Relief It assists with maintaining functional stability when symptoms related to physical discomfort from fluid retention interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Spiromide?

This section outlines the eligibility criteria and official contraindications for Spiromide (a combination of spironolactone and furosemide) as documented in government regulatory sources.

Contraindications (Must Not Use)

Spiromide is strictly contraindicated for individuals with several conditions, primarily related to kidney and electrolyte function. Patients must not use this medicine if they have:

  • Severe Renal Impairment (Creatinine Clearance < 30 mL/min) or Anuria (inability to produce urine).
  • Hyperkalaemia (high blood potassium levels) or Addison's disease.
  • Hypersensitivity (allergy) to either furosemide or spironolactone.
  • Acute renal insufficiency, renal failure due to poisoning, or renal failure associated with hepatic coma.
  • Concomitant use of eplerenone.

Restricted and Conditional Use

Use is not suitable for children (under 18 years of age) due to insufficient established data. The medicine is not recommended for women who are breastfeeding. During pregnancy, use is discouraged unless the anticipated medical benefit significantly outweighs the potential hazard. Special caution and close medical monitoring are required for patients with severe liver diseases (risk of encephalopathy), hypotension, diabetes mellitus, and gout.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Spiromide, a fixed-dose combination of Furosemide and Spironolactone, establishes several crucial interaction patterns, primarily centered on electrolyte balance and blood pressure.


Contraindicated Combinations and Restrictions

Co-administration with Potassium Supplements and other Potassium-Sparing Diuretics (e.g., Amiloride, Triamterene, Eplerenone) is not recommended or should be avoided due to the significantly increased risk of severe hyperkalemia (high serum potassium levels). Additionally, the use of potassium-containing salt substitutes should be avoided for the same reason.

Pharmacodynamic and Exposure Interactions

Interacting Agent/Category Official Documented Interaction Pattern
Lithium Reduces Lithium excretion, leading to elevated plasma concentrations and toxicity risk.
ACE Inhibitors/ARBs Causes an increase in serum potassium concentration and a pronounced fall in blood pressure.
NSAIDs Can attenuate the diuretic/antihypertensive effect and increase the risk of hyperkalemia.
Ototoxic/Nephrotoxic Drugs May potentiate the ototoxicity (e.g., Aminoglycosides) or nephrotoxicity (e.g., Cephalosporins) of these agents.

Administration Timing Rule

Sucralfate must not be taken within two hours of Spiromide due to its interference with the absorption of the Furosemide component.

Population Considerations

For patients with Hepatic Cirrhosis, minor changes in electrolyte balance due to the diuretic action may precipitate hepatic encephalopathy.

Mechanism of Action

Spiromide is a fixed-dose combination containing furosemide and spironolactone. The two components exert distinct, yet complementary, pharmacodynamic actions on renal function.

Furosemide is an inhibitor of the Na+-K+-2Cl− cotransporter (NKCC2) located on the luminal membrane of cells in the thick ascending limb of the loop of Henle. This action blocks the reabsorption of sodium, potassium, and chloride ions from the tubular fluid, leading to an acute, marked increase in solute delivery to the distal nephron. This ultimately produces a robust increase in urinary volume and sodium excretion (natriuresis).

Spironolactone, the second component, functions as a non-selective competitive antagonist of the mineralocorticoid receptor (MR), primarily in the distal convoluted tubule and collecting duct. By blocking the receptor, spironolactone inhibits the genomic and non-genomic actions of aldosterone. The downstream cascade involves reduced expression and function of the epithelial sodium channel (ENaC) and the renal outer medullary potassium channel (ROMK). The net intracellular consequence is the diminished reabsorption of sodium ions and water and a concomitant reduction in the secretion and excretion of potassium ions. The combination yields enhanced systemic modulation of fluid volume and electrolyte balance.

Dosage and Administration Information

Spiromide, a fixed-dose combination (FDC) of Furosemide and Spironolactone, is intended strictly for oral administration as a tablet. The medicine's use is outlined in guidelines that detail its administration pattern, dosage limits, and patient-specific restrictions.

The standard adult daily dosage typically ranges from one to four tablets, depending on the strength prescribed (e.g., Furosemide 20 mg/Spironolactone 50 mg). This daily total may be taken as a single administration or divided into multiple doses.

Instruction Category Guideline
Timing in relation to meals Best taken at breakfast and/or lunch.
Preparation requirements Taken with a generous amount of liquid.
Age-group rules Not suitable for use in children; in older adults, the lowest possible dose should be used due to potentially slower component excretion.
Special conditions Evening administration is not recommended.

The fixed-dose combination is generally reserved for use in patients with conditions that have proven refractory to treatment with a single diuretic component alone. Usage protocol requires prior titration with the individual components before starting the FDC. This highly structured approach dictates the precise context and timing for the medicine's administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Spiromide

This overview describes the official research that has been conducted to study the combination of Furosemide and Spironolactone. This information explains the types of studies available, the patient groups examined, and what remains unclear in the research landscape, without offering any clinical advice or interpretation.


Evidence for Use in Patients Studied for Fluid Retention in Heart Conditions

Research has explored the use of the Spiromide combination in patients with chronic heart failure that were studied for fluid retention (edema). Studies primarily include Randomized Controlled Trials (RCTs) and comparative studies. These studies were designed to evaluate the combination strategy against single-agent therapy or other standard approaches. Outcomes monitored included changes in the patient's physical function, measured by tools like the NYHA functional class, and major clinical endpoints like re-hospitalization rates for heart failure events. Reports derived from the research describe that the combination strategy was evaluated in diverse groups, including older adults and those with mild-to-moderate symptoms.


Evidence for Use in Patients Studied for Fluid Retention Due to Liver Conditions

The combination was evaluated in research exploring ascites (fluid buildup in the abdomen) in patients with cirrhosis of the liver that were studied for fluid retention (ascites). Research included Randomized Comparative Studies that focused on comparing the combination versus using Spironolactone alone. Outcomes research examined included the mobilization of ascites (fluid removal) and the time required to achieve ascites resolution. Findings were sometimes mixed across different research papers when comparing the combination to starting treatment with spironolactone alone.


Gaps and Areas of Research Uncertainty

A consistent gap noted across various indications is the limited availability of specific long-term data for the fixed-dose combination tablet when compared directly against the two components dosed separately. Evidence quality varies across studies, and research does not determine whether an individual will respond similarly outside of those controlled conditions. Data for certain groups, such as the pediatric population (children), remain insufficient or limited.

Key Studies & References

  1. Spiromide Tablets (Spironolactone / Furosamide) Summary of Product Characteristics (SmPC) - Rwanda FDA
  2. Fixed-dose combination diuretics in congestive heart failure: an evaluation

Frequently Asked Questions (FAQ)

Common questions about Spiromide (FAQ)

Q: How quickly should I expect to feel different after starting Spiromide?

A: The official information notes that Furosemide, one component of Spiromide, starts its fluid-removing effect relatively quickly after administration. However, the other component, Spironolactone, has a more gradual effect. Because of this, the full, maximum therapeutic benefit from the combination may require several days or weeks of consistent use to fully manifest.

Q: What are the most common side effects people report when taking Spiromide?

A: Regulatory documents classify the most frequent adverse effects ('Very Common') as those related to fluid and electrolyte balance. These include effects such as dehydration (volume depletion), dizziness, and low sodium (Hyponatraemia). High potassium levels (Hyperkalaemia) are also a commonly documented effect.

Q: Can Spiromide affect my potassium levels, and if so, how?

A: Yes, this medicine is specifically designed to affect potassium levels. One component (Furosemide) tends to lower potassium, while the other (Spironolactone) is a potassium-sparing diuretic that tends to raise potassium. Because of these opposing effects, the net result on an individual's potassium level can vary, and monitoring is often needed.

Q: What happens if I accidentally miss a dose of Spiromide?

A: Official administration instructions generally advise taking a missed dose as soon as you remember. However, if it is close to the time for the next scheduled dose, regulatory guidance suggests skipping the missed dose. Instructions also specify that evening administration is not recommended to avoid disturbing sleep.

Q: Do I need to get regular blood tests while taking Spiromide?

A: Yes. Due to the significant risk of changes in electrolyte balance, particularly potassium and kidney function (creatinine), regulatory guidance specifies that regular blood monitoring is necessary. This monitoring is particularly important when treatment begins or when the dosage is adjusted.

Q: Why do doctors prescribe Spiromide for conditions other than heart failure?

A: According to official product information, Spiromide is indicated for managing severe fluid retention (edema) associated with various conditions. This includes fluid buildup in the abdomen (ascites) caused by cirrhosis of the liver, and it is also approved for treating high blood pressure (hypertension) that is resistant to single-agent diuretic therapy.

Q: How long does it take for the full effect of Spiromide to be noticeable?

A: While the medicine's fluid removal action begins quickly, the full, sustained therapeutic benefit from the combination may require longer. Regulatory information suggests the maximum effect, particularly from the Spironolactone component, may require several days to weeks of consistent use to fully manifest.

Q: Can Spiromide be crushed or split if it is hard to swallow?

A: No. Official guidance indicates that the tablet should be swallowed whole, without chewing or crushing. This ensures that the fixed-dose combination of the two active ingredients is delivered as intended.

Q: What are the typical benefits seen by patients on Spiromide?

A: The primary benefit of Spiromide is its powerful synergistic effect that helps the body remove excess salt and water. This action helps relieve fluid overload (edema) and supports blood pressure control. Clinical studies have assessed outcomes such as improved physical function and reduced hospitalizations related to fluid buildup.

Q: Does Spiromide have any impact on mental clarity or mood?

A: Official safety documents list adverse effects on the Nervous System, including dizziness and headache. While 'mood' changes are not directly listed, official information documents effects on the Central Nervous System (CNS) such as dizziness.

Q: Is Spiromide a common medication for managing hypertension (high blood pressure)?

A: Spiromide is officially indicated as an antihypertensive agent. It is specifically approved for treating resistant hypertension, which is high blood pressure that has not responded adequately to standard diuretic treatments alone.

Q: How often do people need a dosage adjustment with Spiromide?

A: Dosage is highly individualized based on patient response. Regulatory documents for the components suggest that dosage adjustments, if necessary, may be made at intervals of two weeks or more after reviewing clinical and laboratory results.

Q: Does Spiromide cause any weight gain or loss?

A: Weight loss may occur as an intended result of the medicine's diuretic action, as it helps remove excess fluid and sodium from the body. Weight gain is not commonly listed as a direct adverse reaction in official safety documentation.

Q: Is it normal to feel a little dizzy when first taking Spiromide?

A: Yes, this is a documented and common side effect. Symptomatic low blood pressure (hypotension) is noted to be more likely at the start of treatment due to the fluid-removing action.

Q: Are there any foods or drinks I need to avoid while on Spiromide?

A: Yes. Patients are advised in official instructions to avoid the use of potassium-containing salt substitutes because of the high risk of dangerously high potassium levels (hyperkalaemia). Alcohol may also increase the risk of low blood pressure side effects.

Q: What are the signs that my body might not be handling Spiromide well?

A: Signs that your body may not be handling the medication well include excessive dizziness, persistent fatigue, muscle weakness, or cramping. The most serious warning signs relate to very high potassium levels (Hyperkalaemia) or issues related to existing liver conditions, which would require seeking medical attention.

Q: Does Spiromide affect blood sugar levels?

A: Yes, regulatory documents indicate that Furosemide, one component of Spiromide, may cause hyperglycemia (increased blood sugar). Caution is noted in the official product information for patients with pre-existing diabetes mellitus.

Q: Can Spiromide be taken at the same time as my vitamins and supplements?

A: Regulatory information specifically advises against using potassium supplements due to the risk of dangerously high potassium levels. Because the label is silent on most other vitamins and supplements, any potential interactions must be assessed individually.

Q: Is fatigue a common side effect of Spiromide?

A: Fatigue is a recognized adverse reaction for the Spironolactone component of the drug. It may also occur indirectly as a consequence of hypovolaemia (volume depletion), which is a very common effect documented in official safety information.

Q: Can Spiromide cause muscle cramps or spasms?

A: Yes. Muscle cramps are a documented adverse reaction associated with the Spironolactone component. Cramping may also be a symptom of an underlying electrolyte imbalance (either low or high potassium) caused by the medicine.

Q: Does alcohol consumption change how Spiromide works in the body?

A: Yes. Official information notes that alcohol may have additive effects in lowering blood pressure. This can increase the risk of side effects like dizziness, lightheadedness, and fainting when combined with Spiromide.

Q: Is Spiromide known to cause any skin reactions or rashes?

A: Yes. Rashes are reported as a documented adverse reaction in official safety documents. Rarer, more severe skin reactions, which require immediate attention, are also documented.

Q: Does taking Spiromide at night interrupt sleep due to urination?

A: Yes. Regulatory instructions state that taking Spiromide in the evening is not recommended. This is because the strong diuretic action of the medicine can cause increased urine output (polyuria) that may significantly disrupt sleep.

Q: Can I drive or operate machinery while taking Spiromide?

A: Official guidance recommends using caution and avoiding driving or operating hazardous machinery until you know how the medication affects you. This is because the medicine may cause side effects such as dizziness and a drop in blood pressure.

Q: Are there any studies looking at Spiromide use during pregnancy or breastfeeding?

A: Official regulatory documents state that the use of Spiromide is generally discouraged during pregnancy and not recommended during breastfeeding. This is due to insufficient established safety data and potential risks to the fetus or infant.

Q: Are there any specific warning signs of a serious side effect from Spiromide?

A: Yes. Serious documented risks include signs of severe high potassium (Hyperkalaemia), such as an irregular heartbeat, or the potential for Hepatic Encephalopathy (a serious complication) in those with liver impairment. These signs, if experienced, would require seeking immediate medical attention.

Q: Are there any dietary restrictions I need to be aware of when taking Spiromide?

A: Yes. Patients are officially advised to avoid the use of potassium-containing salt substitutes. Caution should be exercised with other foods or supplements that may significantly affect potassium levels, as the risk of dangerously high potassium exists.

Q: Can Spiromide cause changes in a person's voice?

A: Yes. Voice changes (dysphonia) are a documented adverse reaction that has been associated with the Spironolactone component of the medicine.

How should Spiromide be stored and disposed of?

How to Store and Dispose of Spiromide Tablets

The storage and disposal of Spiromide tablets must strictly adhere to the conditions mandated in official regulatory labeling to maintain the product’s quality.

Required Storage and Protection

Spiromide tablets must be stored at a temperature that is below 30°C. The medicine requires mandatory protection from several environmental elements, including moisture, excessive heat, freezing, and sunlight. A key child-safety requirement is to keep the product out of the reach of children at all times.

Official Disposal Instructions

The disposal of unused or expired tablets is governed by regulatory guidance. The official labeling states that the unused medicine must be disposed of according to local regulations. This instruction ensures pharmaceutical waste is handled safely and in compliance with authorized local procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spiromide found in:

A-Z Index: